Literature DB >> 29663364

Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.

Ka-Kui Chan1, Oscar Gee-Wan Wong1, Esther Shuk-Ying Wong1, Karen Kar-Loen Chan2, Philip Pun-Ching Ip1, Ka-Yu Tse2, Annie Nga-Yin Cheung1,3.   

Abstract

Ovarian clear cell carcinoma (OCCC) is a type of epithelial ovarian cancer that is strongly associated with endometriosis, resistance against conventional chemotherapy and thus poorer prognosis. The expression of inhibitory member of the ASPP family proteins (iASPP) and Polo-like kinase (PLK)1 were significantly higher in OCCC compared to benign cystadenomas and endometriosis. Both protein expressions were found to correlate with chemoresistance in patients with OCCC while high iASPP expression alone was significantly associated with a poor patient survival. The growth of OCCC cell lines, OVTOKO and KK, were inhibited after iASPP silencing. Such effect was related to senescence triggering as evidenced by increased SA-β-Gal staining and p21WAF1/Cip1 expression. Moreover, knockdown of iASPP induced PLK1 downregulation, whereas either genes' silencing sensitized the cells in response to cisplatin treatment. More prominent apoptosis was induced by cisplatin in OCCC cells after the knockdown of either iASPP or PLK1 as evidenced by the formation of more cleaved caspase 3. Heightened chemosensitivity to cisplatin after iASPP knockdown was further demonstrated in in vivo xenograft model. Additionally, both iASPP and PLK1 were shown to regulate autophagic flux as the induction of LC3B-II and LC3 puncta were much less in OCCC cells with either knockdown. Importantly, inhibition of autophagy also enhanced chemosensitivity to cisplatin in OCCC cells. These findings strongly imply that iASPP and PLK1 affect the chemoresistance of OCCC via the regulation of autophagy and apoptosis. Both iASPP and PLK1 can be potential therapeutic targets for treating OCCC in combination with conventional chemotherapy.
© 2018 UICC.

Entities:  

Keywords:  PLK1; autophagy; chemoresistance; iASPP; ovarian clear cell carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29663364     DOI: 10.1002/ijc.31535

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  ASPP1 deficiency promotes epithelial-mesenchymal transition, invasion and metastasis in colorectal cancer.

Authors:  Dian Liu; Ayse Ertay; Charlotte Hill; Yilu Zhou; Juanjuan Li; Yanmei Zou; Hong Qiu; Xianglin Yuan; Rob M Ewing; Xin Lu; Hua Xiong; Yihua Wang
Journal:  Cell Death Dis       Date:  2020-04-08       Impact factor: 8.469

2.  PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.

Authors:  Hanlin Ma; Yingwei Li; Xiangxiang Wang; Huan Wu; Gonghua Qi; Rongrong Li; Ning Yang; Min Gao; Shi Yan; Cunzhong Yuan; Beihua Kong
Journal:  Cell Death Dis       Date:  2019-02-18       Impact factor: 8.469

3.  A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma.

Authors:  Mengjiao Wu; Yan Wang; Di Yang; Ying Gong; Feng Rao; Rui Liu; Yeerken Danna; Jinting Li; Jiawen Fan; Jie Chen; Weimin Zhang; Qimin Zhan
Journal:  EBioMedicine       Date:  2019-03-12       Impact factor: 8.143

4.  iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition.

Authors:  Shuo Chen; Jiale Wu; Shan Zhong; Yuntong Li; Ping Zhang; Jingyi Ma; Jingshan Ren; Yun Tan; Yunhao Wang; Kin Fai Au; Christian Siebold; Gareth L Bond; Zhu Chen; Min Lu; E Yvonne Jones; Xin Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-08       Impact factor: 11.205

5.  Overexpression of iASPP is required for autophagy in response to oxidative stress in choriocarcinoma.

Authors:  Ka-Kui Chan; Esther Shuk-Ying Wong; Ivy Tsz-Lo Wong; Claire Ling-Yang Cheung; Oscar Gee-Wan Wong; Hextan Yuen-Sheung Ngan; Annie Nga-Yin Cheung
Journal:  BMC Cancer       Date:  2019-10-15       Impact factor: 4.430

6.  Identification of dysregulated miRNAs-genes network in ovarian cancer: An integrative approach to uncover the molecular interactions and oncomechanisms.

Authors:  Sepideh Kadkhoda; Farzaneh Darbeheshti; Javad Tavakkoly-Bazzaz
Journal:  Cancer Rep (Hoboken)       Date:  2020-09-04

7.  BRDT promotes ovarian cancer cell growth.

Authors:  Ling Chen; Shang Cai; Jing-Mei Wang; Ying-Ying Huai; Pei-Hua Lu; Qian Chu
Journal:  Cell Death Dis       Date:  2020-11-30       Impact factor: 8.469

8.  PLK1 Is a Potential Prognostic Factor Associated with the Tumor Microenvironment in Lung Adenocarcinoma.

Authors:  Lina Wang; Man Gao; Dongjie Sun; Haitao Wu; Shuang Lv; Yulin Li; Lisha Li
Journal:  Biomed Res Int       Date:  2022-07-30       Impact factor: 3.246

Review 9.  PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential.

Authors:  Hai Huang; Mee-Hyun Lee; Kangdong Liu; Zigang Dong; Zeayoung Ryoo; Myoung Ok Kim
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

10.  Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Farid Hashemi; Ebrahim Rahmani Moghadam; Mehdi Raei; Mahshad Kalantari; Shima Tavakol; Reza Mohammadinejad; Masoud Najafi; Franklin R Tay; Pooyan Makvandi
Journal:  ACS Comb Sci       Date:  2020-10-23       Impact factor: 3.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.